<DOC>
	<DOCNO>NCT00107367</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers radiation directly area tumor surgically remove may kill remain tumor cell cause less damage normal tissue . PURPOSE : This phase I/II trial study radiation therapy see well work treat patient undergo surgery remove metastatic brain tumor .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients Who Are Undergoing Surgery Remove Metastatic Brain Tumor</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 1-year local control rate patient undergo resection solitary brain metastasis comprise intraoperative radiotherapy use INTRABEAM® system . Secondary - Determine survival patient treat therapy . - Determine distant recurrence disease patient treat therapy . - Determine toxicity therapy patient . - Determine quality life patient treat therapy . OUTLINE : This nonrandomized study . Patients undergo surgical resection brain metastasis . Patients undergo intraoperative radiotherapy use INTRABEAM® system . Quality life assess baseline every 3 month 2 year . Patients follow within 48 hour surgery , 1 3 month , every 3 month 2 year . PROJECTED ACCRUAL : A total 31-62 patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose supratentorial solitary brain metastasis enhance MRI CT scan Resectable disease Histological evidence metastatic carcinoma intraoperative pathology No primary lymphoma , germ cell carcinoma , small cell lung cancer PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy At least 3 month Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No uncontrolled hypertension No unstable angina pectoris No uncontrolled dysrhythmias Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious infection No medical illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior temozolomide polifeprosan 20 carmustine implant ( Gliadel® wafer ) brain metastasis Endocrine therapy Not specify Radiotherapy No prior brain radiotherapy kind , include local whole brain external beam radiotherapy , brachytherapy , stereotactic radiosurgery No concurrent external beam radiotherapy brain Not plan adjuvant whole brain radiotherapy study therapy Surgery Not specify Other No prior conventional investigational local systemic agent brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>tumor metastatic brain</keyword>
</DOC>